Turning Point Therapeutics Names Homa Yeganegi Senior Vice President, Project Team Leader and Head of Medical Affairs
In this role, Ms. Yeganegi will lead the global product development team responsible for Turning Point Therapeutics’ lead drug candidate, repotrectinib, and as head of Medical Affairs will support the ongoing physician education associated with the company’s three clinical-stage drug candidates in four ongoing clinical studies. Ms. Yeganegi will report to President and Chief Executive Officer
“Homa is a proven and strategic leader with deep experience in oncology drug development and commercial readiness, including supporting physician education and product development for large, global oncology indications,” said Dr. Countouriotis. “She is the ideal leader for our cross-function development team for repotrectinib and a valuable addition to our leadership team.”
Ms. Yeganegi has extensive experience building and leading oncology-focused global Medical Affairs teams, most recently as senior vice president and global program leader at Halozyme, where she was responsible for commercialization strategy and operational planning for the company’s investigational oncology drug candidate. Ms. Yeganegi previously served as vice president of Global Medical Affairs at
She received her B.S. in Biology from the
“Turning Point has built an impressive and highly differentiated pipeline of drug candidates and I look forward to working with Athena and the team to continue their clinical development and deepen physicians’ understanding of the potential they may offer patients,” said Ms. Yeganegi.
About
Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib, which is currently being studied in a registrational Phase 2 study in adults and a Phase 1/2 study in pediatric patients, has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients. The company’s pipeline of drug candidates also includes TPX-0022, targeting MET, CSF1R and SRC, which is currently being studied in a Phase 1 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in MET; and TPX-0046, targeting RET and SRC, which is currently being studied in a Phase 1/2 trial of patients with advanced or metastatic solid tumors harboring genetic alterations in RET. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment. For more information, visit www.tptherapeutics.com.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “plans”, “will”, “believes,” “anticipates,” “expects,” “intends,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Turning Point Therapeutics’ current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with Turning Point Therapeutics’ business in general, and the other risks described in Turning Point Therapeutics’ filings with the
Contact:
jim.mazzola@tptherapeutics.com
858-342-8272
Source: Turning Point Therapeutics, Inc.
